Biocon Agrees to Settlement With Amgen to Market Osteoporosis Treatments

Dow Jones

Oct 01

By Nicholas G. Miller

Biocon Biologics agreed to a settlement-and-license agreement with Amgen that will allow it to market drugs that are highly similar to Amgen treatments for osteoporosis and cancer-related bone conditions.

The FDA last month approved the two Biocon drugs, called Bosaya and Aukelso, and the pact allows India-based Biocon to launch the drugs Wednesday.

The drugs are biosimilars to Amgen's Prolia and Xgeva drugs, which both use the active ingredient denosumab. Thousand Oaks, Calif.-based Amgen recorded $1.12 billion in worldwide Prolia sales and $532 million in Xgeva sales in its fiscal second quarter.

The terms of the settlement are confidential, Biocon said.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

October 01, 2025 08:04 ET (12:04 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2572536204"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572536204\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572536204?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572536204","market":"hk","top_or_hot":-1,"title":"Biocon Agrees to Settlement With Amgen to Market Osteoporosis Treatments","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Biocon Biologics agreed to a settlement-and-license agreement with Amgen that will allow it to market drugs that are highly similar to Amgen treatments for osteoporosis and cancer-related bone conditions. \n</p>\n<p>\n  The FDA last month approved the two Biocon drugs, called Bosaya and Aukelso, and the pact allows India-based Biocon to launch the drugs Wednesday. \n</p>\n<p>\n  The drugs are biosimilars to Amgen's Prolia and Xgeva drugs, which both use the active ingredient denosumab. Thousand Oaks, Calif.-based Amgen recorded $1.12 billion in worldwide Prolia sales and $532 million in Xgeva sales in its fiscal second quarter. \n</p>\n<p>\n  The terms of the settlement are confidential, Biocon said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 01, 2025 08:04 ET (12:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocon Agrees to Settlement With Amgen to Market Osteoporosis Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocon Agrees to Settlement With Amgen to Market Osteoporosis Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-01 20:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Biocon Biologics agreed to a settlement-and-license agreement with Amgen that will allow it to market drugs that are highly similar to Amgen treatments for osteoporosis and cancer-related bone conditions. \n</p>\n<p>\n  The FDA last month approved the two Biocon drugs, called Bosaya and Aukelso, and the pact allows India-based Biocon to launch the drugs Wednesday. \n</p>\n<p>\n  The drugs are biosimilars to Amgen's Prolia and Xgeva drugs, which both use the active ingredient denosumab. Thousand Oaks, Calif.-based Amgen recorded $1.12 billion in worldwide Prolia sales and $532 million in Xgeva sales in its fiscal second quarter. \n</p>\n<p>\n  The terms of the settlement are confidential, Biocon said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 01, 2025 08:04 ET (12:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2242646821.SGD","symbol_name":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2572536204","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572536204","pubTimestamp":1759320240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Biocon Biologics agreed to a settlement-and-license agreement with Amgen that will allow it to market drugs that are highly similar to Amgen treatments for osteoporosis and cancer-related bone conditions.The FDA last month approved the two Biocon drugs, called Bosaya and Aukelso, and the pact allows India-based Biocon to launch the drugs Wednesday.The drugs are biosimilars to Amgen's Prolia and Xgeva drugs, which both use the active ingredient denosumab. Thousand Oaks, Calif.-based Amgen recorded $1.12 billion in worldwide Prolia sales and $532 million in Xgeva sales in its fiscal second quarter.The terms of the settlement are confidential, Biocon said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4139":"生物科技","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","AMGN":"安进","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4566":"资本集团","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4588":"碎股","BK4581":"高盛持仓","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4599":"减肥药"},"translate_title":"Biocon同意与安进达成和解以销售骨质疏松症治疗药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Biocon Biologics agreed to a settlement-and-license agreement with Amgen that will allow it to market drugs that are highly similar to Amgen treatments for osteoporosis and cancer-related bone conditions. \n\n\n  The FDA last month approved the two Biocon drugs, called Bosaya and Aukelso, and the pact allows India-based Biocon to launch the drugs Wednesday. \n\n\n  The drugs are biosimilars to Amgen's Prolia and Xgeva drugs, which both use the active ingredient denosumab. Thousand Oaks, Calif.-based Amgen recorded $1.12 billion in worldwide Prolia sales and $532 million in Xgeva sales in its fiscal second quarter. \n\n\n  The terms of the settlement are confidential, Biocon said. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 01, 2025 08:04 ET (12:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}